Pramipexole regulates the depressive-like symptom through dopamine D3 not dopamine D2 receptor in a mouse model of Parkinson’s disease
Objective: The aim of this study is to understand if the antidepressant effect of pramipexole is mediated by D2R or D3R in a mouse model…Synchronization Study of Regional Local Field Potential in Rat with Dopamine Receptor Stimulation
Objective: The aim of this study attempts to explore the non-linear interaction with cross-frequency coupling in rats during the stimulation of dopamine receptors. Background: Investigating…Usefulness of Cardiac MIBG Scintigraphy, DAT scan and midbrain/pontine ratio to differentiate Parkinson disease from atypical parkinsonian syndrome
Objective: The purpose of this study was to evaluate the usefulness of cardiac 123I-metaiodobenzylguanidine (MIBG) uptake, Dopamine transporter (DAT) scan and midbrain/pontine ratio (M/P ratio)…Relationship between striatal dopamine depletion and various non-motor symptoms in non-demented patients with Parkinson’s disease: a pilot study
Objective: We aimed to investigate associations of striatal dopamine uptake and various non-motor symptoms in non-demented patients with Parkinson’s disease (PD). Background: Dopamine transporter (DAT)…Appropriateness of DAT Scan Ordering in a University Hospital Practice
Objective: To examine the diagnostic utility (or misuse) of DAT scanning in a University Hospital practice – is there unnecessary utilisation of DAT scanning when…Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease
Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early stage Parkinson’s disease. Background: Tavapadon is a potent,…Treatment monitoring using objective and frequent digital testing in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial
Objective: This study evaluates the feasibility, reliability, and validity of smartphone app-based testing in patients with Parkinson’s disease (PD) in the D1PAM (D1 positive allosteric…Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia
Objective: Introduce the mechanism of action for dopamine D1 positive allosteric modulator (D1PAM) as a new target for neuropsychiatric disorders. Describe the preclinical profile of…Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson’s disease
Objective: To identify dopamine transporter status of corpus striatum and thalamus using magnetic resonance imaging-guided spatial normalization method in patients with PD according to olfactory…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.